- Inovio Pharmaceuticals ( NASDAQ: INO ) beat on the top line but fell short on the bottom line in its Q2 2022 results as net loss widened 32% compared to the prior-year period to ~$108.5M.
- Net loss, basic and diluted, was -$0.46 compared to -$0.39 basic and diluted in Q1 2021.
- Revenue of ~$784.4K was a ~189% year-over-year increase.
- Total operating expenses of $104.9 was a ~26% increase compared to Q1 2021.
- Inovio ended the quarter with cash and cash equivalents of $348.1M compared to $401.3M on Dec 31, 2021.
- Seeking Alpha's Quant Rating views Inovio ( INO ) as a hold with high marks for revisions and valuation .
For further details see:
Inovio beats on the top line but misses on the bottom; quarterly net loss widens 32%